GENeral practitioners and Embolism pRevention in NVAF patients treated with RivAroxaban : reaL life evidence

GENeral practitioners and Embolism pRevention in NVAF patients treated with RivAroxaban : reaL life evidence - GENeRAL

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000019135

Enrollment

5000

Registered

2015-09-28

Start date

2015-09-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-valvular atrial fibrillation

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Non-valvular atrial fibrillation patient who are prescribed Rivaroxaban by General pracctitioners.

Exclusion criteria

Exclusion criteria: - Patients are contraindicated for rivaroxaban - Patients judged as inappropriate for this study by investigators

Design outcomes

Primary

Measure	Time frame
Composite of symptomatic stroke (ischemic or hemorrhagic) and systemic embolism	—

Secondary

Measure	Time frame
- Major Bleeding events (adapeted ISTH standard) - Non Major Bleeding events (without Major Bleeding complications) - Composite of symptomatic stroke (ischemic or hemorrhagic), systemic embolism, myocardial infarction/unstable angina pectoris and cardiovascular death - symptomatic stroke (ischemic or emorrhagic) - symptomatic ischemic stroke - symptomatic hemorrhagic stroke - systemic embolism - Acute myocardial infarction/unstable angina pectoris - cardiovascular death - Deep vein thrombosis/pulmonary thromboembolism - Transient ischemic attack - percutaneous coronary intervention/coronary artery bypass grafting - All-cause death - Comparison the primary outcomes and Major Bleeding complications (adapeted ISTH standard) between EXPAND study and FUSHIMI AF registory - Adverse Event excluding hemorrhagic events - Patients adherence related with stroke or systemic embolism - Correlation with CHADS2 score or other risk factors and outcome events in Japanese patients who administered Rivaroxaban.	—

Measure

Time frame

- Major Bleeding events (adapeted ISTH standard) - Non Major Bleeding events (without Major Bleeding complications) - Composite of symptomatic stroke (ischemic or hemorrhagic), systemic embolism, myocardial infarction/unstable angina pectoris and cardiovascular death - symptomatic stroke (ischemic or emorrhagic) - symptomatic ischemic stroke - symptomatic hemorrhagic stroke - systemic embolism - Acute myocardial infarction/unstable angina pectoris - cardiovascular death - Deep vein thrombosis/pulmonary thromboembolism - Transient ischemic attack - percutaneous coronary intervention/coronary artery bypass grafting - All-cause death - Comparison the primary outcomes and Major Bleeding complications (adapeted ISTH standard) between EXPAND study and FUSHIMI AF registory - Adverse Event excluding hemorrhagic events - Patients adherence related with stroke or systemic embolism - Correlation with CHADS2 score or other risk factors and outcome events in Japanese patients who administered Rivaroxaban.

—

Countries

Japan

Contacts

Public ContactSaburo Saito

Japan Cardiovascular Research Foundation Administration Office

general@jcvrf.jp+81-6-6872-0010

Outcome results